Green shoots in Sweden, Norway weighs

EBIT 3% below, outlook reiterated

EBIT -3% vs cons due to Norway. ÖoB better despite sales miss: Outlook unchanged; '26 cons EBIT down ~2%, stock to follow.

Norway clear, Sweden cloudy

Photocure ASA: 1 director

A director at Photocure ASA maiden bought 13,500 shares at 55.210NOK and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

One hot, one not

'26 ÖoB weaker

EBIT -3% vs cons on a small GM / Opex miss. Sales better. ÖoB below and do not expect EBIT improvement in '26. Unchanged '26 EBIT in ÖoB yoy will take cons '26 EBIT down 6-7%.

Solid report not rewarded enough

Solid report – continued signs of scaling

Stock down 25%, we return to BUY

Solid Q3 expected

Too many Cevira dreams priced in

Delivering the goods

Improvements in Q2

Strong core, Swede needs more

Better on higher sales

EBIT +18% vs cons on 3% better sales. ÖoB better than cons and celar q-o-q improvement

Stable ground, numbers on track

Soft quarter, but the penalty has been served

PhotoCure (Buy, TP: NOK80.00) - Generally in line

Photocure reported c7% YOY product revenue growth for Q1, but operating expenses rose substantially, resulting in EBIT of NOK-5.6m, down YOY from NOK0.7m in Q1 2024. The company reiterated its guidance for 2025. A webcast is scheduled for today at 14:00 CET.

Weak US

Tariff proof